NasdaqGM:ESPRPharmaceuticals
Esperion Therapeutics (ESPR) Is Down 15.3% After Discounted $75M Equity Raise Will Dilution Redefine Its Growth Path?
Earlier this week, Esperion Therapeutics completed a public offering of 30 million shares of its common stock at US$2.50 per share, raising approximately US$75 million in gross proceeds.
The offering was priced at a meaningful discount, enabling Esperion to fund the commercial expansion of its cholesterol drugs, development programs, and general operations.
We'll now assess how this substantial equity raise and increased share count could influence Esperion's investment narrative and future...